Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Pilot Study Using Amyloid Reactive Peptide AT-01(124I-evuzamitide) in Transthyretin Cardiac Amyloidosis for Early Detection, Assessment of Cardiac Involvement in Rare Variants and Quantification of Extra-Cardiac Amyloidosis

Next Previous
X
Search
Trial Profile

A Pilot Study Using Amyloid Reactive Peptide AT-01(124I-evuzamitide) in Transthyretin Cardiac Amyloidosis for Early Detection, Assessment of Cardiac Involvement in Rare Variants and Quantification of Extra-Cardiac Amyloidosis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Aug 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AT 01 (Primary)
  • Indications Amyloidosis
  • Focus Diagnostic use

    • Most Recent Events

    • 05 Aug 2024 According to an Attralus media release, drug, 124I-evuzamitide (AT-01), has been granted Breakthrough Therapy Designation (BTD) by the U.S. Food and Drug Administration (FDA) for positron emission tomography (PET) imaging in patients with suspected or known cardiac amyloidosis. based on clinical data from this study.
    • 12 Jul 2024 Status changed to completed.
    • 05 Feb 2024 Planned End Date changed from 1 Mar 2024 to 1 Sep 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top